FDA advisory panel to consider adding experimental peptides to compounding pharmacy list

The FDA's Pharmacy Compounding Advisory Committee (PCAC) is convening Thursday and Friday to review seven experimental peptide substances that have been nominated for the agency's 503A Bulks List, which permits state-licensed compounding pharmacies to prepare customized medications for patients with valid prescriptions.

Committee members, who are largely health-care professionals that prescribe, produce or promote peptides, will assess whether the lack of robust clinical trial data justifies allowing these compounds to be compounded. FDA experts have prepared briefing documents indicating that evidence on safety and efficacy is insufficient, and they have recommended that the peptides not be added to the list.

Supporters argue that regulated compounding could provide a safer alternative to purchasing peptides online from unverified sources. Scott Brunner, chief executive officer of the Alliance for Pharmacy Compounding, said the panel's decision could create a lawful pathway for pharmacies to make and dispense these products, but noted the difficulty of evaluating substances that lack clinical trial data.

Critics warn that permitting broader access through pharmacies may give the impression that the peptides are proven safe and effective, despite limited trial evidence. "We currently don’t know the long-term effects of many of these peptides; what are their toxicities, adverse effects or even their drug interactions," said Edgar Asebey, a life-science attorney. Dr. Eric Topol described the proposal as "a disaster in the works" because of the absence of safety data.

If the committee recommends inclusion, the FDA would still make the final decision, as its advisory opinions are not binding. Inclusion would require patients to obtain a physician's prescription and receive the product from a licensed 503A compounding pharmacy, potentially reducing reliance on the unregulated online market. The outcome could shape how emerging peptide therapies are accessed and regulated in the United States.